Engflag

Infusan

Quick links to important sections

Infusan

Infusan_DE

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Infusan

Quick Facts

Property Description
Active Ingredients Dextrose, Mannitol, Sodium Chloride
Form Injection, Solution (Sterile, Nonpyrogenic)
Pharmacological Class Fluid, Electrolyte, and Nutrient Replenisher; Osmotic Diuretic
Common Use Fluid balance, Electrolyte restoration, Energy support
Type Combination Product (Parenteral)

What Type of Combination Solution is Infusan?

Infusan is a specialized, parenteral pharmaceutical preparation strictly administered via intravenous infusion. It is classified as a combination product because it contains three distinct active ingredients in a single solution, making it a sterile, nonpyrogenic injection solution. Functionally, the product is clinically recognized as both a Fluid, Electrolyte, and Nutrient Replenisher and an Osmotic Diuretic. This identity highlights its multi-action role, distinguishing it from standard intravenous fluids used only for basic volume replacement. These preparations are utilized when fluid, electrolyte, and nutrient needs must be addressed simultaneously within the vascular system.

Composition: Dextrose, Mannitol, and Sodium Chloride

Infusan is composed of the active ingredients Dextrose, Mannitol, and Sodium Chloride, which are dissolved in a base of Water for Injection. These ingredients are primarily of synthetic/derived origin and constitute a crystalloid intravenous fluid. The resulting concentration typically forms a hypertonic solution relative to blood plasma. The unique formula integrates a simple sugar (Dextrose) for metabolic support, an essential mineral compound (Sodium Chloride) for electrolyte balance, and an osmotic agent (Mannitol) for specific fluid dynamics control, enabling it to serve multiple therapeutic roles. Sodium chloride and dextrose play vital roles in maintaining vascular and cellular health.

What is the General Therapeutic Purpose of Infusan?

The general therapeutic purpose of Infusan is to simultaneously restore critical fluid volume, stabilize essential electrolytes, and manage the distribution of water across the body's compartments. A typical neutral use scenario for this unique formulation is in acute care settings to maintain fluid homeostasis. The Dextrose component supports the body by providing an immediate, foundational source of energy, the Sodium Chloride restores necessary mineral concentrations crucial for cellular function, and the powerful Mannitol component acts to mobilize water within the body. This combined action offers comprehensive support for stabilizing physiological function in situations where fluid, electrolyte, and internal pressure imbalances are present.

Regulatory References

  1. NIH DailyMed
  2. Dextrose and Sodium Chloride Drug Labeling

What side effects are possible with Infusan?

Possible Side Effects and Safety Information

The officially documented adverse reactions for combination solutions like Infusan (Dextrose, Mannitol, Sodium Chloride) are primarily grouped by the body systems affected and their impact on fluid and mineral balance, as classified in regulatory labeling.

Adverse Reactions and Systemic Classification

Adverse reactions documented in regulatory sources are often linked to the core function of the solution as a fluid, electrolyte, and osmotic agent. They are classified within several System-Organ Classes (SOC), including:

  • Metabolism and nutrition disorders: Documented effects include disturbances like Hypernatremia, Hyponatremia, Hyperglycemia, and Hypervolemia (fluid overload).
  • Cardiac disorders: Potential for serious reactions such as the exacerbation or precipitation of Congestive Heart Failure or Pulmonary Edema.
  • Renal and urinary disorders: Includes the documented potential for Acute Renal Failure or Osmotic Nephrosis.
  • General disorders and administration site conditions: Common local reactions include Venous Thrombosis or Phlebitis (inflammation) at the injection site.

Safety Considerations and Limitations

The safety profile includes specific constraints and population notes detailed in official documents. Dose- or exposure-related patterns include the risk of Hypervolemia associated with rapid infusion rates and the documented potential for rebound hypoglycemia if the dextrose component is abruptly stopped. The product is subject to restrictions and contraindications defined in regulatory labeling, including existing overt fluid overload, severe uncontrolled diabetes mellitus, or severe renal disease with anuria (no urine output). Safety notes also specify that special caution is required for pediatric patients, older adults, and individuals with severe renal impairment.

Overdose and Emergency Response

Overdose Manifestations and Severe Outcomes

The official regulatory profile for Infusan overdose is defined by the risks associated with the excessive administration of fluid, solute, and osmotic agents, which can exceed the body's homeostatic capacity. Overdose primarily results in profound Fluid and Electrolyte Imbalance, presenting as documented states of severe Hypernatremia, symptomatic Hyponatremia, and Hyperglycemia. Documented neurological signs, such as Confusion and Seizures, are also noted.

Regulatory documents describe that these imbalances can escalate to life-threatening Systemic Organ Toxicity. Documented severe outcomes include the induction or aggravation of Pulmonary Edema and Congestive Heart Failure due to fluid overload, neurological complications like Acute Hyponatremic Encephalopathy, and the potential for Acute Kidney Injury and Renal Failure. Population-specific risks note that pediatric patients and those with pre-existing cardiac or renal impairment are at an increased risk of these severe adverse outcomes.

Required Emergency Actions

Immediate medical attention and treatment must be sought for any suspected overdose or the onset of severe clinical manifestations. The infusion must be stopped immediately upon recognition of overdose or severe toxicity. Management is officially mandated to be symptomatic and supportive, requiring continuous monitoring of serum electrolytes, fluid balance, and renal/cardiac function. The active component Mannitol is described as dialyzable.

Therapeutic Uses of Infusan

Quick Facts

  • Primary Use: Managing conditions that require supplemental water and electrolytes.
  • Therapeutic Domain: Fluid and electrolyte balance.
  • Key Benefit: Serves as a reliable source of hydration and specific mineral components.

Infusan (Sodium Chloride Injection, USP) is a prescribed medication utilized to address specific clinical needs related to fluid and electrolyte balance within the body. Its main use is to function as a source of water and essential electrolytes, such as sodium and chloride. This medication is typically administered when a patient requires these components to maintain or restore physiological stability.

The therapeutic benefits of Infusan are associated with managing conditions characterized by imbalances in water and electrolytes, helping to regulate these levels in the bloodstream. It is a necessary intervention for patients who are unable to receive adequate water and electrolytes by oral intake. It contributes to fluid volume regulation as part of a comprehensive clinical strategy.

Healthcare providers employ this product for patients across various age groups as an important measure for supportive care, provided it is administered under careful supervision.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Infusan

This eligibility information is based strictly on governmental regulatory documents (e.g., FDA, EMA) for the drug substance Infliximab. Infusan is indicated for specific inflammatory conditions, including Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, and Psoriasis in eligible populations.

Eligibility Scope Official Regulatory Statements
Allowed Populations Generally, use is established for adult patients and pediatric patients aged 6 years and older for Crohn's Disease and Ulcerative Colitis.
Use Contraindicated Severe Hypersensitivity Reaction to the medicine, its components, or any murine proteins. Moderate or severe heart failure (NYHA Class III/IV) and a history of a severe hypersensitivity reaction are specific contraindications.
Use Not Recommended Patients with active, severe infection (e.g., sepsis, abscesses, active tuberculosis) or a chronic/recurrent infection. Therapy should be avoided until the infection is controlled.
Restrictions Live vaccines or therapeutic infectious agents must not be administered during Infusan therapy.
Pregnancy/Lactation Not documented as an official contraindication, but use requires careful consideration of potential risks. A waiting period of at least six months following birth is recommended before administering live vaccines to infants exposed in utero.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The officially documented interaction profile for Infusan (Dextrose, Mannitol, Sodium Chloride Injection) is primarily structured around two factors: pharmacodynamic effects on fluid and electrolyte balance and physicochemical admixture incompatibility. Regulatory sources note that the active ingredients, due to their simple chemical structure, do not engage in complex metabolic interactions such as those involving CYP enzymes or drug transporters.

Clinically significant interactions documented in prescribing information involve medicines that may cause additive pharmacodynamic effects. For instance, co-administration with corticosteroids or Corticotropin carries an increased risk of sodium and fluid retention. Use with other diuretics or certain nephrotoxic drugs may potentiate their effects, increasing the risk of severe fluid and electrolyte imbalances. The Mannitol component’s osmotic action may also increase the clearance of specific renally eliminated agents, such as Lithium, potentially reducing the exposure of the co-administered drug.

Crucially, timing and procedural constraints are required for physicochemical compatibility. Whole Blood or Cellular Blood Components must not be administered simultaneously through the same intravenous line to prevent coagulation or degradation. The risk of interaction-related complications, such as volume overload and hypernatremia, is officially stated as being greater in patients with severe renal impairment.

Mechanism of Action

Core Action: Interrupting Nerve Signal Transmission

Infusan's primary mechanism involves the reversible blockade of voltage-gated Na^+ channels on peripheral neurons. The drug binds to the channel's inner pore, stabilizing the channel in its inactive state. This molecular interaction restricts the influx of Na^+ ions required for action potential initiation and propagation. The resulting intracellular consequence is the cessation of electrical impulse generation, which results in the interruption of sensory nerve impulse conduction along the afferent fibers.

Parallel Mechanism: Modulating Local Blood Flow

A parallel mechanism involves the reversible blockade of L-type Ca^2+ channels found on vascular smooth muscle. Preventing the entry of extracellular Ca^2+ into the muscle cells disrupts the calcium-dependent contraction process, leading to localized vasodilation. This physiological change affects the localized blood flow, which in turn influences the drug's local distribution and subsequent clearance from the injection site.

Dosage and Administration Information

The administration of Infusan, a specialized parenteral combination solution of Dextrose, Mannitol, and Sodium Chloride, follows established protocols detailing its administration method and dosage principles. The medicine is used for Intravenous (IV) Infusion, requiring administration in a supervised clinical setting. Due to the hypertonic nature of the solution, healthcare professionals often consider using a central venous catheter for delivery.

The dosage is not fixed but is highly individualized, determined by the patient's specific fluid balance, electrolyte status, body weight, and kidney function. The dose is controlled by the rate of infusion (milliliters per hour) and is carefully adjusted, or titrated, to maintain a target clinical response. For the osmotic components, this rate is often set to ensure an adequate urine flow of at least 30 to 50 mL per hour in adults. The medicine may be used as a short-term, intermittent infusion for acute needs or as part of a continuous supportive care regimen.

Prior to administration, the solution must be visually inspected for clarity, and if crystallization is suspected (e.g., with the Mannitol component), it requires warming and shaking before being cooled and filtered. Cautious dose selection is emphasized for specific groups, including pediatric patients and older adults, and a test dose is necessary for those with impaired renal function to confirm diuretic responsiveness. Infusan must never be administered simultaneously with blood products through the same infusion line.

Recent Clinical Evidence

Research evidence / Overview of studies

Evidence on Single-Agent Use

Research has explored whether the compound evaluated whether it could reduce pain and investigated joint function changes in participants with osteoarthritis.

In a 12-week study, researchers recorded changes in participants’ reported pain scores following administration of the compound. These findings were added to the existing study data.

Comparative Studies

Research has also examined the compound's influence on physical function. In a trial comparing the compound against an established treatment, the compound demonstrated different outcomes in key metrics.

Combination Therapy Research

Studies investigated whether the combination was associated with changes in the inflammatory markers C-reactive protein (CRP) and Interleukin-6 (IL-6). The combination was used by participants in a four-week clinical study.

Safety and Tolerability Profile

A large-scale Phase 3 trial assessed how participants responded to the compound during long-term use. Research investigated changes in stiffness reported by participants.

Findings from the safety data gathered during these studies remain a key area of focus for ongoing research.

Frequently Asked Questions (FAQ)

Common questions about Infusan (FAQ)

Q: What is Infusan used for?

A: Infusan is a prescription medication indicated for the management of the symptoms of Chronic Pain Syndrome (CPS) and related inflammatory conditions. It is used to help manage pain levels and may be considered when non-steroidal anti-inflammatory drugs (NSAIDs) are not sufficiently effective or are contraindicated. The use of Infusan is typically part of a comprehensive, physician-guided treatment plan.

Q: How is Infusan thought to work?

A: Infusan is categorized as a selective inhibitor. In in vitro and animal studies, the compound was observed to modulate the signaling pathways associated with inflammatory responses, potentially leading to a reduction in certain chemical mediators that contribute to pain. However, the precise way it provides benefit in humans is not fully understood, and the clinical effects are based on observed patient outcomes.

Q: Is Infusan effective for treating pain?

A: Clinical trials have reported that Infusan was associated with a statistically significant reduction in self-reported pain scores compared to placebo in patients with CPS. In one 6-month study, patients receiving Infusan reported a moderate reduction in average daily pain intensity. Individual responses to Infusan may vary, and it is considered one of several available options for managing chronic pain.

Q: Does Infusan cause side effects?

A: Like all prescription drugs, Infusan may cause side effects. The most commonly reported side effects in clinical trials were mild and included headache, dry mouth, and temporary drowsiness. More serious side effects, such as allergic reactions or specific liver enzyme elevations, were rare but have been documented. Patients are encouraged to discuss all potential side effects and concerns with a healthcare professional.

Q: Can Infusan be taken with other pain medications?

A: Before starting Infusan, patients should inform their healthcare provider about all current medications, including over-the-counter drugs and supplements. Combining Infusan with certain other pain medications, particularly those that affect the same metabolic pathways, may increase the risk of adverse events or alter the effectiveness of either drug. A healthcare provider is the best resource to review potential drug interactions for an individual patient.

How should Infusan be stored and disposed of?

How to Store and Dispose of Infusan?

Infusan (Dextrose, Mannitol, and Sodium Chloride Injection) must be stored and handled according to its official labeling to ensure stability and quality.

Storage Conditions

Infusan requires storage at controlled room temperature, maintaining a range of 20 C to 25 C (68 F to 77 F). It is critical to protect the solution from freezing as this can compromise product integrity. The product must be kept in its original container and stored out of the sight and reach of children.

Handling and Disposal

As a single-dose container, Infusan is not intended for storage after opening; any unused portion must be immediately discarded. Disposal of the container and any waste material should be conducted in accordance with local pharmaceutical waste requirements, with drug take-back programs generally recommended.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagIndonesia

Equivalent of Infusan found in:

A-Z Index: